Quartet Medicine, a Cambridge, Mass.-based biotechnology company focused on the development of novel treatments for chronic pain and inflammation, raised $17m in Series A financing.
The round was led by Atlas Venture with participation from Novartis Venture Funds, Pfizer Venture Investment and Partners Innovation Fund. In conjunction with the funding, Henry Skinner from Novartis Venture Funds joined Quartet’s board of directors.
The company intends to use the funds to advance its lead program targeting the modulation of tetrahydrobiopterin (BH4) synthesis through human proof-of-concept studies.
Co-founded in late 2013 by Kevin Pojasek, Ph.D. while working as an entrepreneur-in-residence at Atlas Venture along with Clifford Woolf, M.D., Ph.D., of Harvard Medical School and Boston Children’s Hospital and Kai Johnsson, Ph.D., of École Polytechnique Fédérale de Lausanne (EPFL), Quartet Medicine focuses on discovering and developing novel treatments for chronic pain and inflammation via restoring tetrahydrobiopterin (BH4) as a critical mediator of peripheral nerve dysfunction and immune cell regulation.